Pay in 4 interest-free payments of $5.18 Learn more
Ships within 48 hours · Estimated delivery Aug 22 - Aug 27
The compound's potential to mimic hepatocyte growth factor (HGF) signalling made it theoretically attractive for addressing this core pathology
Beyond 6 months of chronic undereating: Menstrual irregularities or loss
Data were averaged across 3-monthly blocks (HbA1c, GMI, TIR, Hypos, CoV, %basal) at baseline and at 3 and 6 months after system commencement
Complementary approaches may include: Behavioral therapy or weight management counseling Sleep optimization (79 hours nightly) Stress management techniques Evaluation and treatment of coexisting conditions (insulin resistance, sleep apnea, depression) FDA-approved oral weight loss medications (orlistat, phentermine/topiramate ER, naltrexone/bupropion) as alternatives to injectables (note: phentermine monotherapy is approved for short-term use only) Patients should maintain realistic expectationsweight loss may be slower with hypothyroidism, even when well-controlled
Limited human studies : While there is a growing body of anecdotal evidence supporting its benefits, clinical trials in humans are limited
